Medtronic (NYSE:MDT) said today it has secured reimbursement for its MiniMed 670G insulin pump system from regulators in Germany.

The German Federal Association of the Statutory Health Insurances (GKV-SV) granted reimbursement for the smart insulin pump for patients with type 1 diabetes, according to the company.

In May, Medtronic released real-world data from more than 8 million patient days that showed patients using the MiniMed 670G spent more time in a healthy blood glucose range.

The MiniMed 670G is designed to automatically track and adjust blood sugar levels, using a continuous glucose monitor, guiding patients toward a minimum level of 120 mg/dL. Medtronic first won FDA approval for the MiniMed 670G in September 2016.

“We have already seen the difference the MiniMed 670G system has had for tens of thousands of people living with type 1 diabetes across the world who are now experiencing better clinical and quality of life outcomes,” said Medtronic diabetes group chief medical officer Dr. Robert Vigersky in a news release. “Reimbursement in Germany will increase the access of this life-changing technology to more individuals who would benefit from it.”

The reimbursement agreement took effect on August 29, 2019, according to Medtronic. The company said it expects the approval to be announced in the Federal Gazette  (Bundesanzeiger) in the coming weeks.